Engineered immune cells take on Hard-to-Treat breast cancer
NCT ID NCT05989828
First seen Jan 08, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This early-stage trial tests a personalized cell therapy for people with advanced triple negative breast cancer that has stopped responding to standard treatments. Researchers take a patient's own immune cells, modify them in the lab to recognize a protein called NY-ESO-1 found on cancer cells, and return them to the body to attack the tumor. The study aims to find the safest dose and monitor side effects in up to 20 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.